Pulmonary Nodule Management

Size-Based Malignancy Risk Stratification

The American Thoracic Society recommends that nodules ≥8 mm (or ≥300 mm³) require formal risk stratification using validated prediction models like the Brock model, while nodules <5 mm have an extremely low malignancy risk (<1%) and can be discharged without follow-up 1, 2
Nodules <5 mm have a malignancy probability of <1% and do not require follow-up 2, 3, 4, 5, 1, 6
Small nodules (5-8 mm or 80-300 mm³) have a malignancy probability of 1-6% and require CT surveillance rather than immediate aggressive workup 2, 3, 4, 5, 1, 6
Larger nodules (≥8 mm or ≥300 mm³) have a malignancy probability of 9.7% for ≥8 mm and 16.9% for ≥300 mm³, and require formal risk assessment using the Brock model 4, 5, 1, 6

Benign features such as diffuse, central, laminated, or popcorn calcification patterns, macroscopic fat content, and typical perifissural or subpleural nodules do not require follow-up regardless of size 1, 6
High-risk features such as spiculation, pleural indentation, and upper lobe location increase malignancy probability 8, 4

For nodules ≥8 mm without benign features, calculate malignancy risk using the Brock model, and manage based on risk: <10% risk, consider PET-CT or CT surveillance; 10-70% risk, PET-CT with Herder model reassessment or consider biopsy; >70% risk, proceed to excision or non-surgical treatment 1, 6, 7, 9, 3
For nodules 5-8 mm, CT surveillance at 3 months and 1 year to assess volume doubling time, and use ≥25% volume change to define significant growth 1, 8
For nodules <5 mm, discharge without follow-up 1, 6

Do not assume all nodules in patients with known cancer are metastases—evaluate each nodule individually as >85% may be benign 10
Do not rely on PET-CT for nodules <8 mm—sensitivity is inadequate for small nodules 1, 5
Do not use diameter measurements alone—volumetric assessment (mm³) is more accurate, though software variability exists 4, 5
Do not ignore patient risk factors—current smokers and patients ≥65 years have higher malignancy rates even for same-sized nodules 2, 3